Currently, there are few methods to effectively reintroduce the immune response in PC models, prompting the question of whether it is more advantageous to devote time and resources towards improving PD-1 and PD-L1 inhibitors or provide resources to therapies with proven potential in treating late-stage PC. Here, PDCD1 is linked to pachyonychia congenita.